These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19723499)

  • 41. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
    Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
    J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.
    Jilka RL; O'Brien CA; Bartell SM; Weinstein RS; Manolagas SC
    J Bone Miner Res; 2010 Nov; 25(11):2427-37. PubMed ID: 20533302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Signaling pathways governing osteoblast proliferation, differentiation and function.
    Chau JF; Leong WF; Li B
    Histol Histopathol; 2009 Dec; 24(12):1593-606. PubMed ID: 19795357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of signal-selective parathyroid hormone analogue peptide on expressions of Wnt signaling factors].
    Feng R; Jiang J; Li J; Fu Z; Lin Z; Yuan L; Yang D
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2012 Apr; 26(4):472-6. PubMed ID: 22568332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ERβ induces the differentiation of cultured osteoblasts by both Wnt/β-catenin signaling pathway and estrogen signaling pathways.
    Yin X; Wang X; Hu X; Chen Y; Zeng K; Zhang H
    Exp Cell Res; 2015 Jul; 335(1):107-14. PubMed ID: 25957463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix.
    Zhang C; Cho K; Huang Y; Lyons JP; Zhou X; Sinha K; McCrea PD; de Crombrugghe B
    Proc Natl Acad Sci U S A; 2008 May; 105(19):6936-41. PubMed ID: 18458345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory.
    Jeannet G; Boudousquié C; Gardiol N; Kang J; Huelsken J; Held W
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9777-82. PubMed ID: 20457902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Msx2 exerts bone anabolism via canonical Wnt signaling.
    Cheng SL; Shao JS; Cai J; Sierra OL; Towler DA
    J Biol Chem; 2008 Jul; 283(29):20505-22. PubMed ID: 18487199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.
    Marie PJ; Kassem M
    Eur J Endocrinol; 2011 Jul; 165(1):1-10. PubMed ID: 21543379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
    Qiang YW; Hu B; Chen Y; Zhong Y; Shi B; Barlogie B; Shaughnessy JD
    Blood; 2009 Apr; 113(18):4319-30. PubMed ID: 19196662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
    Esbrit P; Alcaraz MJ
    Biochem Pharmacol; 2013 May; 85(10):1417-23. PubMed ID: 23500550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts.
    Jilka RL; O'Brien CA; Ali AA; Roberson PK; Weinstein RS; Manolagas SC
    Bone; 2009 Feb; 44(2):275-86. PubMed ID: 19010455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Rho GTPase RAC1 in Osteoblasts Controls Their Function.
    Huck K; Sens C; Wuerfel C; Zoeller C; Nakchbandi IA
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in the transduction of canonical Wnt signals demarcate effector and memory CD8 T cells with distinct recall proliferation capacity.
    Boudousquié C; Danilo M; Pousse L; Jeevan-Raj B; Angelov GS; Chennupati V; Zehn D; Held W
    J Immunol; 2014 Sep; 193(6):2784-91. PubMed ID: 25127860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of Bone Remodeling by Parathyroid Hormone.
    Wein MN; Kronenberg HM
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29358318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T cells potentiate PTH-induced cortical bone loss through CD40L signaling.
    Gao Y; Wu X; Terauchi M; Li JY; Grassi F; Galley S; Yang X; Weitzmann MN; Pacifici R
    Cell Metab; 2008 Aug; 8(2):132-45. PubMed ID: 18680714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
    Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC
    Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of bone development and maintenance by Runx2.
    Komori T
    Front Biosci; 2008 Jan; 13():898-903. PubMed ID: 17981598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.